These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 34690930)

  • 1. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes.
    Shao S; Yang Q; Pan R; Yu X; Chen Y
    Front Endocrinol (Lausanne); 2021; 12():731974. PubMed ID: 34690930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
    Filardi T; Morano S
    J Endocrinol Invest; 2020 Aug; 43(8):1053-1060. PubMed ID: 32495299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and diabetes mellitus: from pathophysiology to clinical management.
    Lim S; Bae JH; Kwon HS; Nauck MA
    Nat Rev Endocrinol; 2021 Jan; 17(1):11-30. PubMed ID: 33188364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.
    Drucker DJ
    Endocr Rev; 2020 Jun; 41(3):. PubMed ID: 32294179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues.
    Subbarayan K; Ulagappan K; Wickenhauser C; Bachmann M; Seliger B
    Front Immunol; 2021; 12():597399. PubMed ID: 33796097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
    Krejner-Bienias A; Grzela K; Grzela T
    Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):1. PubMed ID: 33527308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.
    Herman-Edelstein M; Guetta T; Barnea A; Waldman M; Ben-Dor N; Barac YD; Kornowski R; Arad M; Hochhauser E; Aravot D
    Cardiovasc Diabetol; 2021 Apr; 20(1):90. PubMed ID: 33906662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
    Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
    Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
    Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
    J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route.
    de Oliveira AP; Lopes ALF; Pacheco G; de Sá Guimarães Nolêto IR; Nicolau LAD; Medeiros JVR
    Med Hypotheses; 2020 Nov; 144():110243. PubMed ID: 33254549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19.
    Chen CF; Chien CH; Yang YP; Chou SJ; Wang ML; Huo TI; Lin CC
    J Chin Med Assoc; 2020 Aug; 83(8):710-711. PubMed ID: 32349031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cell receptors: potential drug targets to combat COVID-19.
    Raghav PK; Kalyanaraman K; Kumar D
    Amino Acids; 2021 Jun; 53(6):813-842. PubMed ID: 33950300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1.
    Shin J; Toyoda S; Nishitani S; Onodera T; Fukuda S; Kita S; Fukuhara A; Shimomura I
    Metabolism; 2022 Aug; 133():155236. PubMed ID: 35688210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
    Foroozanfar E; Forouzanfar M; Farkhondeh T; Samarghandian S; Forouzanfar F
    Curr Drug Discov Technol; 2021; 18(6):e130921189567. PubMed ID: 33371835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.